Opioid Therapy for Chronic Pain

New England Journal of Medicine

Volumn 349, Issue 20, 2003, Pages 1943-1953

  Ballantyne, Jane C ^a   Mao, Jianren ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CODEINE; FENTANYL; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; LEVORPHANOL; METHADONE; MORPHINE; MORPHINE SULFATE; OPIATE; OXYCODONE; PARACETAMOL; PERCOCET; PERCODAN; PETHIDINE;

ANALGESIA; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; HUMAN; IMMUNOPATHOLOGY; MYOCLONUS; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLOW RELEASE FORMULATION;

ALGORITHMS; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DRUG TOLERANCE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; NARCOTICS; PAIN; PITUITARY-ADRENAL SYSTEM; TREATMENT FAILURE;

EID: 0242658912     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra025411     Document Type: Review

References (101)

1. Hill CS Jr. Government regulatory influences on opioid prescribing and their impact on the treatment of pain of nonmalignant origin. J Pain Symptom Manage 1996;11:287-98.
2. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986;25:171-86.
3. McQuay H. Opioids in pain management. Lancet 1999;353:2229-32.
4. Turk DC, Brody MC, Okifuji EA. Physicians' attitudes and practices regarding the long-term prescribing of opioids for non-cancer pain. Pain 1994;59:201-8.
5. Ready LB, Sarkis E, Turner JA. Self-reported vs. actual use of medications in chronic pain patients. Pain 1982;12:285-94.
6. Turner JA, Calsyn DA, Fordyce WE, Ready LB. Drug utilization pattern in chronic pain patients. Pain 1982;12:357-63.
7. McNairy SL, Maruta T, Ivnik RJ, Swanson DW, Ilstrup DM. Prescription medication dependence and neuropsychologic function. Pain 1984;18:169-77.
8. Buckley FP, Sizemore WA, Charlton JE. Medication management in patients with chronic non-malignant pain: a review of the use of a drug withdrawal protocol. Pain 1986;26:153-65.
9. Finlayson RE, Maruta T, Morse RM, Martin MA. Substance dependence and chronic pain: experience with treatment and follow-up results. Pain 1986;26:175-80.
10. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain Symptom Manage 1993;8:279-88.
11. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Glenview, Ill.: American Academy of Pain Medicine and American Pain Society, 1997.
12. Model guidelines for the use of controlled substances for the treatment of pain: a policy document of the Federation of State Medical Boards of the United States Inc. Dallas: Federation of State Medical Boards of the United States, 1998.
13. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage 1996;11:203-17.
14. Fishman SM, Mao J. Opioid therapy in chronic nonmalignant pain. In: Ballantyne JC, ed. The Massachusetts General Hospital handbook of pain management. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
15. Urban BJ, France RD, Steinberger EK, Scott DL, Maltbie AA. Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1986;24:191-6.
16. Tennant FS Jr, Uelmen GF. Narcotic maintenance for chronic pain: medical and legal guidelines. Postgrad Med 1983;73:81-3, 86-8, 91-4.
17. Bouckoms AJ, Masand P, Murray GB, Cassem EH, Stern TA, Tesar GE. Chronic nonmalignant pain treatment with long term analgesics. Ann Clin Psychiatry 1992;4:185-92.
18. Zenz M, Strumpf M, Tryba M. Long-term opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992;7:69-77.
19. Pappagallo M, Raja SN, Haythornthwaite JA, Clark M, Campbell JN. Oral opioids in the management of postherpetic neuralgia: a prospective survey. Analgesia 1994;1:S1-S5.
20. Gardner-Nix JS. Oral methadone for managing chronic nonmalignant pain. J Symptom Pain Manage 1996;11:321-8.
21. Lorenz J, Beck H, Bromm B. Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic nonmalignant pain. Pain 1997;73:369-75.
22. Simpson RK Jr, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl for chronic low back pain. J Pain Symptom Manage 1997;14:218-24.
23. Ytterberg SR, Mahowald ML, Woods SR, Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum 1998;41:1603-12.
24. Altier N, Dion D, Boulanger A, Choiniere M. Successful use of methadone in the treatment of chronic neuropathic pain arising from bum injuries: a case-study. Bums 2001;27:771-5.
25. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-6.
26. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995;346:667-70.
27. Galski T, Willimas JB, Ehle HT. Effects of opioids on driving ability. J Pain Symptom Manage 2000;19:200-8.
28. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15:185-94.
29. Max J, Price DD, Mayer DH. Association of pain relief with drug side-effects in post-herpetic neuralgia: a single dose study of clonidine, codeine, ibuprofen and placebo. Clin Pharmacol Ther 1988;43:363-71.
30. Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991;41:1024-8.
31. Dellemijn PL, Vanneste JA. Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753-8.
32. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
33. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HL. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992;339:1367-71.
34. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-32.
35. Foley KM. Opioids and chronic neuropathic pain. N Engl J Med 2003;348:1279-81.
36. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and opiate tolerance: a current view of their possible interactions. Pain 1995;62:259-74.
37. Bian D, Ossipov MH, Ibrahim M, et al. Loss of antiallodynic and antinociceptive spinal/supraspinal morphine synergy in nerve-injured rats: restoration by MK-801 or dynorphine antiserum. Brain Res 1999;831:55-63.
38. Kjaersgaard-Andersen P, Nafei A, Skov O, et al. Codeine plus paracetamol versus paracetamol in longer-term treatment of chronic pain due to osteoarthritis of the hip: a randomised, double-blind, multi-centre study. Pain 1990;43:309-18.
39. Moran C. MST continuous tablets and pain control in severe rheumatoid arthritis. Br J Clin Res 1991;2:1-12.
40. Arkinstall W, Sandler A, Goughnour B, Babul N, Harsanyi Z, Darke AC. Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain 1995;62:169-78.
41. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain: a randomized prospective study. Spine 1998;23:2591-600.
42. Sheather-Reid RB, Cohen M. Efficacy of analgesics in chronic pain: a series of N-of-1 studies. J Pain Symptom Manage 1998;15:244-52.
43. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
44. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862-9.
45. Schofferman J. Long-term opioid analgesic therapy for severe refractory lumbar spine pain. Clin J Pain 1999;15:136-40.
46. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-7.
47. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the hip or knee. J Rheumatol 2000;19:764-71.
48. Roth SH, Fleischmann RM, Burch RX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med 2000;160:853-60.
49. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278-91.
50. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a double-blind placebo-controlled trial (MONTAS). Pain 2002;97:223-33.
51. Raja SN, Haythornthwaite JA, Pappagallo, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
52. Grisel JE, Watkins LR, Maier SF. Associative and non-associative mechanisms of morphine analgesic tolerance are neuro-chemically distinct in the rat spinal cord. Psychopharmacology (Berl) 1996;128:248-55.
53. Mitchell JM, Basbaum AI, Fields HL. A locus and mechanism of action for associative morphine tolerance. Nat Neurosci 2000;3:47-53.
54. Alvarez V, Arttamangkul S, Williams JT. A RAVE about opioid withdrawal. Neuron 2001;32:761-3.
55. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001;32:829-39.
56. South SM, Smith MT. Analgesic tolerance to opioids. Pain Clinical Updates. December 2001:1-4.
57. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251:85-7.
58. Marek P, Ben-Eliyahu S, Vaccarino AL, Liebeskind JC. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res 1991;558:163-5.
59. Tiseo PJ, Inturrisi CE. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J Pharmacol Exp Ther 1993;264:1090-6.
60. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain 1994;56:69-75.
61. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994;14:2301-12.
62. Manning BH, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain 1996;67:79-86.
63. Brodner RA, Taub A. Chronic pain exacerbated by long-term narcotic use in patients with non-malignant disease: clinical syndrome and treatment. Mt Sinai J Med 1978;45:233-7.
64. Taylor CB, Zlutnick SI, Corley MJ, Flora J. The effects of detoxification, relaxation, and brief supportive therapy on chronic pain. Pain 1980;8:319-29.
65. Savage SR. Long-term opioid therapy: assessment of consequences and risks. J Pain Symptom Manage 1996;11:274-86.
66. Compton MA. Cold-pressor pain tolerance in opiate and cocaine abusers: correlates of drug type and use status. J Pain Symptom Manage 1994;9:462-73.
67. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995;61:353-64.
68. Mao J, Sung B, Ji RR, Lim G. Neuronal apoptosis associated with morphine tolerance: evidence for an opioid-induced neurotoxic mechanism. J Neurosci 2002;22:7650-61.
69. Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995;42:891-903.
70. Giffard RG, Morgan RL. Cell death in the central nervous system: therapeutic possibilities? Reg Anesth Pain Med 2000;25:22-5.
71. Mao J, Sung B, Ji RR, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002;22:8312-23.
72. Mao J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002;100:213-7.
73. Banki CM, Arato M. Multiple hormonal responses to morphine: relationship to diagnosis and dexamethasone suppression. Psychoneuroendocrinology 1987;12:3-11.
74. Collu R, Clermont MJ, Ducharme JR. Effects of thyrotropin-releasing hormone on prolactin, growth hormone and corticosterone secretions in adult male rats treated with pentobarbital or morphine. Eur J Pharmacol 1976;37:133-40.
75. Bartolome MB, Kuhn CM. Endocrine effects of methadone in rats: acute effects in adults. Eur J Pharmacol 1983;95:231-8.
76. Rolandi E, Marabini A, Franceschini R, Messina V, Bongera P, Barreca T. Changes in pituitary secretion induced by an agonist-antagonist opioid drug, buprenorphine. Acta Endocrinol (CoPenh) 1983;104:257-60.
77. Malaivijitnond S, Varavudhi P. Evidence for morphine-induced galactorrhea in male cynomolgus monkeys. J Med Primatol 1998;27:1-9.
78. Mendelson JH, Mendelson JE, Patch VD. Plasma testosterone levels in heroin addiction and during methadone maintenance. J Pharmacol Exp Ther 1975;192:211-7.
79. Mendelson JH, Meyer RE, Ellingboe J, Mirin SM, McDougle M. Effects of heroin and methadone on plasma cortisol and testosterone. J Pharmacol Exp Ther 1975;195:296-302.
80. Rasheed A, Tareen IA. Effects of heroin on thyroid function, cortisol and testosterone level in addicts. Pol J Pharmacol 1995;47:441-4.
81. Malik SA, Khan C, Jabbar A, Iqbal A. Heroin addiction and sex hormones in males. J Pak Med Assoc 1992;42:210-2.
82. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85:2215-22.
83. Finch PM, Roberts LJ, Price L, Hadlow NC, Pullan PT. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000;16:251-4.
84. Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res 1996;21:1375-86.
85. Risdahl JM, Khanna KV, Peterson PK, Molitor TW. Opiates and infection. J Neuroimmunol 1998;83:4-18.
86. Makman MH. Morphine receptors in immunocytes and neurons. Adv Neuroimmunol 1994;4:69-82.
87. Rahim RT, Adler MW, Meissler JJ Jr, et al. Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol 2002;127:88-95.
88. Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol 1997;121:834-40.
89. De Waal EJ, Van Der Laan JW, Van Loveren H. Effects of prolonged exposure to morphine and methadone on in vivo parameters of immune function in rats. Toxicology 1998;129:201-10.
90. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990;4:869-73.
91. Kusnecov AW, Rabin BS. Stressor-induced alterations of immune function: mechanisms and issues. Int Arch Allergy Immunol 1994;105:107-21.
92. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
93. Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Glenview, Ill.: American Academy of Pain Medicine, 2001.
94. Frances A, Pincus HA, First MB, et al. Substance related disorders. In: Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 2000:191-295.
95. Ballantyne J, ed. The Massachusetts General Hospital handbook of pain management. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:562.
96. Bulka A, Plesan A, Xu XJ, Wiesenfeld-Hallin Z. Reduced tolerance to the antihyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain 2002;95:103-9.
97. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289:1048-53.
98. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical applications with related concerns. Pain Med 2002;3:339-48.
99. Wilson PR, Opioid use and diversion: report on recent hearing by FDA and DEA. ASA statement to FDA committee. ASA Newslett 2002;66(10):9-10.
100. Pasternak GW. The pharmacology of mu analgesics: from patients to genes. Neuroscientist 2001;7:220-31.
101. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999;86:1856-66.